Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35835135

Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2022 Aug
First author
Pautier P

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Oct;23(10):e442. doi: 10.1016/S1470-2045(22)00546-0.
    note
    Source null
    related pmid
    36174623
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2022 Oct;23(10):e443. doi: 10.1016/S1470-2045(22)00574-5.
    note
    Source null
    related pmid
    36174624
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2022 Oct;23(10):e444. doi: 10.1016/S1470-2045(22)00547-2.
    note
    Source null
    related pmid
    36174625
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2022 Oct;23(10):e445. doi: 10.1016/S1470-2045(22)00563-0.
    note
    Source null
    related pmid
    36174626
    relationship
    Comment in

Authors and identifiers

  1. name
    Pautier P
    type
    Author
  2. name
    Italiano A
    type
    Author
  3. name
    Piperno-Neumann S
    type
    Author
  4. name
    Chevreau C
    type
    Author
  5. name
    Penel N
    type
    Author
  6. name
    Firmin N
    type
    Author
  7. name
    Boudou-Rouquette P
    type
    Author
  8. name
    Bertucci F
    type
    Author
  9. name
    Balleyguier C
    type
    Author
  10. name
    Lebrun-Ly V
    type
    Author
  11. name
    Ray-Coquard I
    type
    Author
  12. name
    Kalbacher E
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Pautier P
    type
    Author
  2. name
    Italiano A
    type
    Author
  3. name
    Piperno-Neumann S
    type
    Author
  4. name
    Chevreau C
    type
    Author
  5. name
    Penel N
    type
    Author
  6. name
    Firmin N
    type
    Author
  7. name
    Boudou-Rouquette P
    type
    Author
  8. name
    Bertucci F
    type
    Author
  9. name
    Balleyguier C
    type
    Author
  10. name
    Lebrun-Ly V
    type
    Author
  11. name
    Ray-Coquard I
    type
    Author
  12. name
    Kalbacher E
    type
    Author
bibliography ids
  1. nci-bib-2a83a098b01cd62c83a9b580
book metadata
content sha256
68e6eef5514c01441ac843d94a4d7255d22fddce2ffb3ab94b94a7110a884f26
document type
citation
dois
  1. 10.1016/S1470-2045(22)00380-1
electronic publication date
display
2022 Jul 11
precision
day
year
2022
evidence scope
bibliographic_metadata_only
id
pubmed:35835135
immutable id
pubmed:35835135@68e6eef5514c01441ac843d94a4d7255d22fddce2ffb3ab94b94a7110a884f26
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
8
name
The Lancet. Oncology
nlm unique id
100957246
pages
1044-1054
volume
23
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Oct;23(10):e442. doi: 10.1016/S1470-2045(22)00546-0.
    note
    Source null
    related pmid
    36174623
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2022 Oct;23(10):e443. doi: 10.1016/S1470-2045(22)00574-5.
    note
    Source null
    related pmid
    36174624
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2022 Oct;23(10):e444. doi: 10.1016/S1470-2045(22)00547-2.
    note
    Source null
    related pmid
    36174625
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2022 Oct;23(10):e445. doi: 10.1016/S1470-2045(22)00563-0.
    note
    Source null
    related pmid
    36174626
    relationship
    Comment in
outcomes validated
false
pmid
35835135
provenance
batch id
9d150d55960e0c12aada
provider
NCBI PubMed ESummary
record sha256
896470fd2b2671080a512221dea717fa466bf411dd98dd0998a59344f407fea6
response sha256
2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
retrieved at
2026-09-09T23:48:09.820498+00:00
publication date
display
2022 Aug
precision
month
year
2022
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
  6. Equivalence Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/35835135/
title
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.

Preserved source evidence · Not medical advice